Home > Cardiology > AHA 2022 > Hypertension: Novel Developments > The endothelin system: a new target for resistant high blood pressure

The endothelin system: a new target for resistant high blood pressure

Presented By
Prof. Markus P Schlaich, University of Western Australia, Perth
Conference
AHA 2022
Trial
Phase 3, PRECISION
Doi
https://doi.org/10.55788/92361872
Two different doses of the dual endothelin receptor antagonist aprocitentan were superior to placebo in lowering the systolic blood pressure (SBP) in patients with resistant hypertension, results from the PRECISION trial show. The phase 3 PRECISION trial (NCT03541174) investigated the endothelin receptor antagonist aprocitentan as a treatment option for patients with resistant hypertension [1]. The study consisted of 3 parts and included 730 participants: a 4-week double-blind part with randomisation to either placebo or aprocitentan (12.5 mg or 25 mg), a consecutive single-blinded part of 32 weeks of 25 mg aprocitentan for all participants, and a withdrawal part with re-randomisation to either placebo or 25 mg of aprocitentan for 12 weeks. The study population had a mean age of 62 years, 60% men, over 60% of participants were treated with ≥4 baseline anti-h...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on